Abstract
Advanced prostate cancer (PCa) patients with bone metastases are treated standardly with Androgen Pathway Directed Therapy (APDT), however, they invariably become APDT-resistant. To elucidate resistance mechanisms and to provide more predictive pre-clinical research platforms reflecting tumor heterogeneity, w e established organoids from patient-derived xenograft (PDX) models of bone metastatic prostate cancer. APDT-resistant PDX-derived organoids (PDOs) emerged when cultured without androgen or with the anti-androgen, enzalutamide. Transcriptomics revealed up-regulation of neurogenic and steroidogenic genes and down-regulation of DNA repair, cell cycle, circadian pathways and the severe acute respiratory syndrome (SARS)-CoV-2 host viral entry factors, ACE2 and TMPRSS2. These experiments demonstrated that PDOs can be used to develop therapies targeting dormant APDT-resistant cells and host factors required for SARS-CoV-2 viral entry. Enzalutamide treatment decreased androgen receptor (AR) protein and induced dormant, hybrid basal-luminal cells as shown here for the first time in live organoids using the Fucci2BL fluorescent cell cycle tracker system.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
